AccueilCMPS • NASDAQ
add
Compass Pathways PLC
3,67 $
Après la clôture :(2,18 %)+0,080
3,75 $
Fermé : 3 mars, 16:04:27 UTC−5 · USD · NASDAQ · Clause de non-responsabilité
Dernière clôture
3,93 $
Variation sur la journée
3,66 $ - 4,10 $
Plage sur l'année
3,17 $ - 12,57 $
Capitalisation boursière
339,20 M USD
Volume moyen
1,18 M
Place boursière principale
NASDAQ
Actualités
Données financières
Compte de résultat
Chiffre d'affaires
Résultat net
| (USD) | déc. 2024info | Variation Y/Y |
|---|---|---|
Chiffre d'affaires | — | — |
Charges d'exploitation | 38,21 M | 9,02 % |
Résultat net | -43,33 M | -33,20 % |
Marge bénéficiaire nette | — | — |
Bénéfice par action | -0,63 | -18,87 % |
EBITDA | -38,16 M | -9,06 % |
Taux d'imposition effectif | -2,42 % | — |
Bilan
Total des actifs
Total du passif
| (USD) | déc. 2024info | Variation Y/Y |
|---|---|---|
Trésorerie/Invest. court terme | 165,08 M | -25,03 % |
Total des actifs | 213,67 M | -22,58 % |
Total du passif | 58,97 M | 17,37 % |
Total des capitaux propres | 154,70 M | — |
Actions en circulation | 92,67 M | — |
Ratio cours/valeur comptable | 1,74 | — |
Rentabilité des actifs | -41,44 % | — |
Retour sur capitaux | -46,32 % | — |
Flux de trésorerie
Variation nette en trésorerie
| (USD) | déc. 2024info | Variation Y/Y |
|---|---|---|
Résultat net | -43,33 M | -33,20 % |
Trésorerie (opérations) | -41,76 M | -50,30 % |
Trésorerie (invest.) | — | — |
Trésorerie (financement) | 155,00 k | 278,05 % |
Variation nette en trésorerie | -41,87 M | -50,99 % |
Flux de trésorerie dispo. | -44,04 M | -133,07 % |
À propos
Compass Pathways, or COMPASS Pathways, is a British pharmaceutical company developing psychedelics as potential medicines. Its main drug candidate, psilocybin, is currently in phase 3 clinical trials for treatment-resistant depression. This candidate has received breakthrough therapy status from the U.S. Food and Drug Administration. It is the most advanced psychedelic drug candidate in development besides Lykos Therapeutics's midomafetamine.
Compass Pathways is the largest company in the psychedelic medicine industry and, in 2020, was the first psychedelic medicine company to be listed on the NASDAQ. It has faced criticism for patenting psychedelic drugs and even certain psilocybin mushroom species. In October 2024, after the FDA rejected Lykos Therapeutics's MDMA for post-traumatic stress disorder New Drug Application, Compass Pathways said that it would lay off 30% of its workforce and narrow its research focus.
Compass Pathways has entered partnerships with several independent psychedelic academic scientists, including Jason Wallach, Hamilton Morris, and Adam Halberstadt among others, to develop novel psychedelic drugs for potential medical use. Wikipedia
Date de fondation
13 juin 2016
Site Web
Employés
166
